MetaCap

Alzamend Neuro (ALZN) vs Silo Pharma (SILO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alzamend Neuro is the larger company by market cap ($3.7 million vs $3.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALZN-43.37%SILO+18.75%
+36%-5%-47%
Oct 7, 20261 yearNov 20, 2026
ALZN-42.10%SILO+16.33%
+29%-8%-45%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALZN versus SILO key metrics
MetricALZNSILO
Share price$0.7758$1.71
Market cap$3.74M$3.69M
1-day change-23.94%-9.04%
EPS (TTM)$-2.30$-2.26
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$72.10K
Revenue growth (YoY)—0.00%
Net income (latest FY)$-8.77M$-4.23M
Gross margin—38.57%
Operating margin—-5936.95%
Net margin—-5863.50%
52-week high$2.54$10.43
52-week low$0.754$1.10
Distance from 52-week high-69.40%-83.60%
Analyst consensusnone—
Avg. price target upside+3251.38%—
Average volume70.27K65.47K
Shares outstanding4.83M2.16M
Employees43
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Alzamend Neuro

ALZN stock →

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About Silo Pharma

SILO stock →

Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

ALZN vs SILO FAQ

Which is bigger, Alzamend Neuro or Silo Pharma?

Alzamend Neuro (ALZN) is larger, with a market capitalization of $3.74M compared with $3.69M for Silo Pharma (SILO).

Are Alzamend Neuro and Silo Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons